Why Obesity Leads to More Aggressive Prostate Cancer

635882818915684243waistline.jpg

14 Jan 2016 --- Obesity has direct consequences on health and is associated with the onset of aggressive cancers, but the mechanisms underlying this phenomenon are little known. Researchers from the Institut de Pharmacologie et Biologie Structurale (CNRS/Université Toulouse III - Paul Sabatier) have recently elucidated one of these mechanisms in prostate cancer, one of the most common cancers in men: in obese patients, the adipose tissue surrounding the prostate gland facilitates the spread of tumor cells outside the prostate. A patent has been filed for these results, which open new avenues for the treatment of prostate cancer, and are published in Nature Communications on January 12, 2016.

The prostate is surrounded by a fatty deposit called periprostatic adipose tissue (PPAT). As prostate cancer progresses, tumor cells may infiltrate this periprostatic adipose tissue: this is a key step in the progression of this cancer, as it signals locally advanced disease (where the cancer can progress to nearby organs). This phenomenon is more frequent in obese patients, in whom the size and number of PPAT adipocyte cells are higher. These cells can secrete numerous bioactive molecules such as chemokines, which can attract other cells. The scientists investigated whether this change in PPAT was responsible for the aggressiveness of prostate cancer in obese subjects.

The researchers showed that adipocyte secretions can attract prostate tumor cells. By analyzing chemokines secreted by PPAT adipocytes they identified the factors involved, in particular chemokine CCL7, which interacts with one of its receptors, CCR3, present on the surface of prostate tumor cells. The scientists demonstrated that chemokine CCL7 is diffused through the PPAT to the area around the prostate and that it attracts tumor cells that express the CCR3 receptor towards the periprostatic adipose tissue, the gateway to the rest of the body.

The researchers then tested the influence of obesity on this mechanism. They showed that in obese mice who had been fed a high-fat diet, tumor progression and dissemination outside the prostate is greater than in mice with normal body weight. Adipocytes do indeed secrete more CCL7 in the case of obesity. When tumor cells that no longer express CCR3 are implanted in the prostates of mice, tumor progression and dissemination are significantly reduced, especially in obese mice.

Finally, the researchers observed this same mechanism in men where CCL7 secretion is also higher in case of obesity. The results of a study of more than 100 human tumor samples show that the tumors expressing a high level of CCR3 present more frequent local dissemination. They are also more aggressive and resistant to treatment. Since molecules that target CCR3 have already been developed by the pharmaceutical industry for other diseases, the researchers are now hoping to explore this new therapeutic pathway, which could reduce the aggressiveness of prostate cancer in obese patients.
 

Related Articles

Nutrition & Health News

AI: Nuritas explores potential health benefits during Future of Nutrition Summit

13 Dec 2017 --- Biotechnology company Nuritas has innovative plans for using artificial intelligence (AI) to relieve the potential burden of future global health issues. These plans were outlined during its Future of Nutrition Summit held the day before FiE 2017 in Frankfurt, during which Nuritas Commercial Manager Neil Foster outlined the company’s use of AI for data mining for bioactive peptides, specific molecules with “tremendous” health benefits.

Business News

Vitafoods Europe to examine mainstreaming of personalized nutrition

13 Dec 2017 --- One of the major issues to be discussed at Vitafoods Europe 2018 will be how personalized nutrition can break out of its niche and achieve mass market appeal, the organizers of the global nutraceutical event have announced. Advances in genomics and wearable technology have created new opportunities for products tailored to individual consumers. And in a new poll conducted by the organizers, personalized nutrition ranks as one of the most important industry trends for 2018, behind only clean label and scientifically supported health claims.

Business News

Frutarom finalizes AB-Fortis micro-encapsulation technology acquisition

13 Dec 2017 --- Frutarom has acquired AB-Fortis activities, including a patent-protected micro-encapsulation technology that enables delivery of iron with increased biological absorption. Frutarom announced the signing of an agreement with AB-Biotics S.A. of Spain for the acquisition of the activity of AB-Fortis in November.

Business News

Kappa Bioscience moves to expand vitamin K2 presence in US with new appointments

13 Dec 2017 --- Kappa Bioscience AS, maker of K2Vital vitamin K2 MK-7, has appointed Garnet Pigden and New Jersey-based D2C to head-up the continued development of Kappa’s position in the US market. The appointment spans the establishment of strategy, infrastructure, partnerships and key accounts in support of an overall objective of solidifying vitamin K2 in mainstream US markets and channels, according to Kappa.

Nutrition & Health News

Researchers create app to predict and intervene in users' overeating

13 Dec 2017 --- Researchers at Worcester Polytechnic Institute (WPI) and the University of Connecticut (UConn) are collaborating on a smartphone app aimed at helping users manage their overeating challenges in three key ways: by tracking eating patterns, providing interventions and helping change behavior. According to the researchers, the app and its distinctive methodology have shown “tremendous promise” in an early pilot study.

More Articles
URL : http://www.nutritioninsight.com:80/news/why-obesity-leads-to-more-aggressive-prostate-cancer.html